Cardiome Pharma Corp. Stock Upgraded (CRME)

NEW YORK ( TheStreet) -- Cardiome Pharma Corp (Nasdaq: CRME) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and deteriorating net income.

Highlights from the ratings report include:
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 146.2% when compared to the same quarter one year ago, falling from $15.47 million to -$7.15 million.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 43.21%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 146.15% compared to the year-earlier quarter. Despite the heavy decline in its share price, this stock is still more expensive (when compared to its current earnings) than most other companies in its industry.
  • CARDIOME PHARMA CORP has exprienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past two years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, CARDIOME PHARMA CORP turned its bottom line around by earning $0.58 versus -$0.02 in the prior year.
  • Despite currently having a low debt-to-equity ratio of 0.56, it is higher than that of the industry average, inferring that management of debt levels may need to be evaluated further. Even though the debt-to-equity ratio shows mixed results, the company's quick ratio of 13.93 is very high and demonstrates very strong liquidity.
  • Net operating cash flow has increased to -$7.28 million or 18.43% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -4.63%.

Cardiome Pharma Corp., a life sciences company, engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. The company has a P/E ratio of 24.1, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Cardiome has a market cap of $295.3 million and is part of the health care sector and drugs industry. Shares are down 28.3% year to date as of the close of trading on Tuesday.

You can view the full Cardiome Ratings Report or get investment ideas from our investment research center.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%